ASX:NTI
Neurotech gets another approval around autism.
"The lack of side effects with NTI164 and the significant clinical improvements we've observed in these patients necessitates a long term treatment plan."
ASX:NTI
"The lack of side effects with NTI164 and the significant clinical improvements we've observed in these patients necessitates a long term treatment plan."
NTI
NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN.